Literature DB >> 11826412

Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Igor Dvorchik1, Michael Subotin, A Jake Demetris, John J Fung, Thomas E Starzl, Samuel Wieand, Kareem M Abu-Elmagd.   

Abstract

This report investigates the influence of liver transplantation and concomitant immunosuppression on the course of progression of inflammatory bowel disease (IBD) and discusses statistical methodology appropriate for such settings. The data on 303 patients who underwent liver transplantation for primary sclerosing cholangitis (PSC) were analyzed using person-time analysis and Cox regression, with the duration of IBD as the time variable and transplantation as a segmented time-dependent covariate, to take into account both posttransplant and pretransplant history of IBD. The need for colectomy and appearance of colorectal cancer were taken as outcome measures. The only significant risk factor in the multivariate model for colectomy was transplantation itself, which increased the risk of colectomy due to intractable disease (Wald statistic; P =.001). None of the variables available for analysis were found to influence the risk of colon cancer significantly. Graphs showing the dependence of the instantaneous risk of cancer on the time from onset of IBD and its independence from the latter in the case of colectomy are presented. The use of a unique statistical methodology described for the first time in this setting led us to the somewhat surprising conclusion that transplantation and concomitant use of immunosuppression accelerate the progression of IBD. At the same time, transplantation does not affect the incidence of colorectal cancer. These results confirm the findings of some recent studies and can potentially shed new light on the disease pathogenesis.

Entities:  

Mesh:

Year:  2002        PMID: 11826412      PMCID: PMC2965629          DOI: 10.1053/jhep.2002.30695

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis.

Authors:  H Higashi; K Yanaga; J W Marsh; A Tzakis; S Kakizoe; T E Starzl
Journal:  Hepatology       Date:  1990-03       Impact factor: 17.425

2.  Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum.

Authors:  E Ierardi; M Principi; M Rendina; R Francavilla; M Ingrosso; A Pisani; A Amoruso; C Panella; A Francavilla
Journal:  J Clin Gastroenterol       Date:  2000-03       Impact factor: 3.062

3.  Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae.

Authors:  P W Lowry; A L Weaver; W J Tremaine; W J Sandborn
Journal:  Inflamm Bowel Dis       Date:  1999-11       Impact factor: 5.325

4.  The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation.

Authors:  A Shaked; J O Colonna; L Goldstein; R W Busuttil
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

Review 5.  Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation.

Authors:  D M Rennick; M M Fort
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-06       Impact factor: 4.052

6.  Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis.

Authors:  M Cottone; G Pietrosi; G Martorana; A Casà; G Pecoraro; L Oliva; A Orlando; M Rosselli; A Rizzo; L Pagliaro
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

Review 7.  Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis.

Authors:  G V Papatheodoridis; M Hamilton; P K Mistry; B Davidson; K Rolles; A K Burroughs
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

8.  Assessment of colorectal cancer risk in patients with ulcerative colitis: experience from a private practice.

Authors:  I Katzka; R S Brody; E Morris; S Katz
Journal:  Gastroenterology       Date:  1983-07       Impact factor: 22.682

9.  Cancer in universal and left-sided ulcerative colitis: factors determining risk.

Authors:  A J Greenstein; D B Sachar; H Smith; A Pucillo; A E Papatestas; I Kreel; S A Geller; H D Janowitz; A H Aufses
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

10.  Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis.

Authors:  J S Gavaler; B Delemos; S H Belle; A E Heyl; R E Tarter; T E Starzl; C Gavaler; D H van Thiel
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

View more
  24 in total

Review 1.  Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2002-12

Review 2.  Crohn's disease and infections: a complex relationship.

Authors:  Gert De Hertogh; Karel Geboes
Journal:  MedGenMed       Date:  2004-08-10

Review 3.  Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.

Authors:  Rosy Wang; Rupert W Leong
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

4.  A Review of Inflammatory Bowel Disease in the Setting of Liver Transplantation.

Authors:  Veena Nannegari; Saenz Roque; David T Rubin; Rodrigo Quera
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

Review 5.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 6.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

7.  Treatment of Biliary Problems in Inflammatory Bowel Disease.

Authors:  Christopher S Huang; David R Lichtenstein
Journal:  Curr Treat Options Gastroenterol       Date:  2005-04

Review 8.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 9.  Management of ulcerative colitis pre- and post-liver transplant for primary sclerosing cholangitis: two case reports and review of literature.

Authors:  Kiranpreet Khosa; Kofi Clarke
Journal:  Int J Colorectal Dis       Date:  2014-07-04       Impact factor: 2.571

Review 10.  Avoiding pitfalls: what an endoscopist should know in liver transplantation--part II.

Authors:  Sharad Sharma; Ahmet Gurakar; Cemalettin Camci; Nicolas Jabbour
Journal:  Dig Dis Sci       Date:  2008-12-17       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.